Independent Portfolio Consultants’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Independent Portfolio Consultants’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$9K	Buy	+116	New	+$9.49K	﹤0.01%	734

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Independent Portfolio Consultants's EGRX Position: Q2 2017 in Review

Independent Portfolio Consultants opened a new position in Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2017: 116 shares worth $9K. The stake represents ﹤0.01% of the portfolio and ranks #734 among its holdings.

175 funds tracked by Wall St. Rank hold EGRX as of Q2 2017.

Independent Portfolio Consultants held 116 shares of Eagle Pharmaceuticals, Inc. worth $9K as of Q2 2017.
Eagle Pharmaceuticals, Inc. was a new Independent Portfolio Consultants position in Q2 2017.
Eagle Pharmaceuticals, Inc. made up ﹤0.01% of Independent Portfolio Consultants's portfolio in Q2 2017, its #734 holding.
175 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2017.

Based on Independent Portfolio Consultants's 13F filing for Q2 2017, filed 6 Jul 2017.